Markus Gershater looks at how automation and artificial intelligence (AI) can transform pharma R&D. Due to increasing complexity in R&D, pharma teams are under pressure to drive down costs and ...

and Boehringer Ingelheim/Zealand Pharma start to eye a market that has been estimated to be worth $100 billion within a decade. Data on the subcutaneous version of amycretin is due next year ...